Bret Sellman is Executive Director and Head of Bacterial Vaccine R&D in Early Vaccines and Immune Therapies at AstraZeneca. He has over 22 yrs of industry experience in antibacterial vaccine and monoclonal antibody research and development with >75 peer reviewed publications. He has worked at MedImmune / AstraZeneca for 16 years where he and his team have led various antibacterial monoclonal antibody programs from discovery thru Phase 2 clinical testing and he is currently building a new antibacterial vaccine R&D team. Prior to MedImmune, he worked at Wyeth Vaccine Research as a research lead in bacterial vaccine discovery. He earned his B.S. in microbiology from New Mexico State University and his PhD in microbiology and immunology from the University of Oklahoma Health Sciences Center before completing his post-doctoral training at Harvard Medical School studying bacterial toxin biochemistry.
A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?
10:00 Chair opening remarks
10:10 Accelerating the Development of Novel Tools against AMR Dr Richard Alm, Chief Scientist, CARB-X
10:40 The application of phages to treat bacterial infectionsDr Steven Theriault, CEO & CSO, Cytophage
11:40 The Significance of Robust Health and Economic Data in Tackling Antimicrobial ResistanceLatifat Okara, Principal, Health Policy and Insights, The Economist Impact
12:00-1:00 Panel: What is our AMR strategy: ESKAPE and Priority Pathogens?
Dr Tim Cooke, CEO, Omniose Dr Bret Sellman, Executive Director, Vaccine and Immune Therapies and Head of Bacteriology and Vaccines Discovery, Astrazeneca Dr Francesca Micoli, Director GVGH Innovation Academy and Senior Project Leader, GSK Vaccine Institute for Global Health Dr Kimberly Taylor, Senior Scientific Officer, Concept Acceleration Program, NIAID
1:00 - 2:00 Lunch Break
2:00 Combination Vaccines Dr William Hausdorff, Public Health Value Proposition Lead, PATH
2:30 Shigella and ETEC vaccines Dr Chad Porter, Department Head Translational and Clinical Research Defense Infectious Diseases Directorate, Naval Medical Research Center
3:00 Serotype Independent Pneumococcal Vaccine Dr Tim Hirst, CEO, GPN Vaccines
3:30 Developing Pseudomonas and Klebsiella vaccines using a reverse vaccinology approachDr Rebecca Ingram, Senior Lecturer, Queens University Belfast
3:45 Update on C. diff vaccine development Dr Erik Lamberth, Senior Director, Vaccine Clinical Research and Development, Pfizer
4:00-5:00 Panel: Defining the value of vaccines against AMR
Moderator: Dr Jomana Musmar, Executive Director, PACCARBDr Jessica Pickett, Director, US Vaccines Health Economics and Outcomes Research, GSK Dr Fadi Makki, Partner and Director, BCG Dr John Jernigan, Chief, Epidemiology Research and Innovations Branch Division of Healthcare Quality Promotion, CDC